GLP1R and Obesity: Finally, semaglutide and liraglutide were associated to increased constipation risk, while cagrilinitide and exenatide showed no significant increase.<h4>Conclusions</h4>GLP-1 RAs showed several adverse gastrointestinal effects in non-diabetic patients with overweight or obesity.